{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelin+%28Msln%29", "query": { "condition": "Mesothelin (Msln)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelin+%28Msln%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:00:06.516Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Mesothelioma, Malignant", "Mesothelioma; Pleura", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Cholangiocarcinoma", "Cholangiocarcinoma Recurrent", "Ovarian Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "High Grade Ovarian Serous Adenocarcinoma" ], "interventions": [ { "name": "gavo-cel", "type": "BIOLOGICAL" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TCR2 Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2019-04-15", "completion_date": "2028-11-02", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 10, "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907852" }, { "nct_id": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "NSCLC", "Non Small Cell Lung Cancer", "NSCLC, Recurrent", "Non-Small Cell Squamous Lung Cancer", "Pancreas Cancer", "Pancreatic Neoplasm", "Colorectal Adenocarcinoma", "CRC", "Colon Cancer", "Rectal Cancer", "Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Mesothelioma", "Mesothelioma, Malignant", "Ovary Cancer", "Lung Cancer", "MESOM" ], "interventions": [ { "name": "A2B694", "type": "BIOLOGICAL" }, { "name": "A2B543", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2024-04-03", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 12, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051695" }, { "nct_id": "NCT00585845", "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Epithelial Mesothelioma", "Adenocarcinoma of the Pancreas", "Carcinoma, Non-Small-Cell Lung", "Adenocarcinoma of the Ovaries" ], "interventions": [ { "name": "CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Anza Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2009-02-20", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585845" }, { "nct_id": "NCT00024687", "title": "Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-11-14", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024687" }, { "nct_id": "NCT01675765", "title": "Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "Immunotherapy plus chemotherapy", "type": "BIOLOGICAL" }, { "name": "Immunotherapy with cyclophosphamide plus chemotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-09-03", "completion_date": "2019-08-19", "has_results": true, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 5, "location_summary": "San Francisco, California • Tampa, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01675765" }, { "nct_id": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Adenocarcinoma", "Ovarian Cancer", "Peritoneal Carcinoma", "Fallopian Tube Cancer", "Mesotheliomas Pleural", "Mesothelioma Peritoneum" ], "interventions": [ { "name": "huCART-meso cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2017-04-06", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03054298" }, { "nct_id": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelin-Expressing Tumors", "Epithelial Ovarian Cancer", "Malignant Pleural Mesothelioma, Advanced", "Malignant Peritoneal Mesothelioma, Advanced", "Pancreatic Adenocarcinoma Advanced or Metastatic", "Lung Adenocarcinoma Metastatic", "Cholangiocarcinoma Advanced", "Cholangiocarcinoma Non-resectable", "Mesothelin-expressing Advanced Cancers", "Mesothelin-positive Advanced Malignant Solid Tumors", "Colorectal Cancer" ], "interventions": [ { "name": "CT-95", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Context Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-03-31", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 7, "location_summary": "Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756035" }, { "nct_id": "NCT03644550", "title": "Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "LMB-100", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-04", "completion_date": "2020-11-02", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644550" }, { "nct_id": "NCT04027946", "title": "LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Non-Small Cell Lung Cancer", "Adenocarcinoma of Lung" ], "interventions": [ { "name": "LMB-100", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Mesothelin Expression", "type": "DIAGNOSTIC_TEST" }, { "name": "TrueSight Oncology 500", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-09-11", "completion_date": "2023-12-22", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04027946" }, { "nct_id": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Mesothelioma", "Lung Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-05-04", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-05-22T04:00:06.516Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01583686" } ] }